Secondary outcome measures include changes in DASH-E at 3 and 12 months , changes in pain as assessed by the visual analogue scale ( VAS ) at the 6-week , 3 - , 6 - , and 12-month follow-up , changes in sonographic features and neovascularity , and percentage of patients in each group with adverse reactions at 3 , 6 , and 12 months .